5-MeO-DMT for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

5-MeO-DMT for Health & Longevity

Created on 07/15/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

5-MeO-DMT is an extremely potent, very short-acting psychedelic being studied as a rapid treatment for hard-to-treat depression, with reported gains in anxiety, trauma, and well-being. Its longevity interest is indirect, resting on the link between mental health and long-term health. Evidence is early; serious short-term risks and legal restrictions make safe use dependent on screening and skilled supervision. (Full Review)

Protocol

Route
Inhaled vapor
Precisely dosed, standardized synthetic product over toad secretion
Dosing
Escalate to peak
Individualized dose escalation until a full peak experience; single session
Setting
Supervised clinic
Continuous medical monitoring; morning or midday
Time to effect
Mood improvement
Within ~1 day
Much faster than conventional antidepressants
Afterglow
Days to weeks
Gains in well-being, mindfulness, life satisfaction
Acute onset
Seconds to 1 min
Near-immediate when inhaled; effects resolve in ~15–90 min

Benefits

Contraindications
  • MAOIs
  • Psychotic or bipolar disorder (personal or family history)
  • Significant cardiovascular disease
  • Uncontrolled hypertension (>160/100 mmHg)
  • Recent cardiovascular event (MI within 6–12 months)
  • QTc above ~450–470 ms
  • Seizure disorder
  • Pregnancy or breastfeeding
    •
Key Interactions
  • SSRIs (fluoxetine, sertraline)
  • SNRIs (venlafaxine, duloxetine)
  • CYP2D6 inhibitors (bupropion, paroxetine, fluoxetine)
  • Dextromethorphan
  • St. John's Wort
  • Sympathomimetic decongestants (pseudoephedrine)
  • Serotonergic/MAO-affecting supplements (5-HTP, L-Tryptophan, harmala alkaloids)
  • Other psychedelics, stimulants, or ibogaine
    •

Risk & Side Effects

  • High: Acute overwhelming fear and psychological distress; transient cardiovascular stress
    •
  • Medium: Nausea and vomiting; loss of motor control and injury risk; uncontrolled dosing with toad-derived material
    •
  • Low: Psychosis or mania in predisposed individuals; serotonin toxicity with interacting drugs
    •
  • Speculative: Hallucinogen persisting perception disorder
    •

Monitoring

Marker Target Why
Blood pressure <120/80 mmHg Screens cardiovascular safety before an acute pressor effect
Resting heart rate 50–70 bpm Baseline for the acute rise in heart rate
ECG (QTc interval) <440 ms (men) / <460 ms (women) Detects arrhythmia risk before a serotonergic pressor
Liver enzymes (ALT, AST) ALT ~10–25 U/L; AST ~10–26 U/L Liver enzymes clear the compound and its active metabolite

Cadence: Baseline before any session; reassess mood and adverse effects at 1 day, 1 week, and 4 weeks, then every 3–6 months if benefit is maintained; repeat cardiovascular screening before any additional session

Qualitative Assessment

  • Depression and anxiety symptom levels (self-rated before and after)
  • Sleep quality and restfulness
  • Energy and daily functioning
  • Sense of meaning, life satisfaction, and psychological flexibility
  • Quality of relationships and re-engagement with valued activities
  • Psychiatric screen: no personal or family history of mania or psychosis
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.